Univariable analysis | Multivariable analysis | |||
---|---|---|---|---|
Unadjusted OR (95% CI) | p | Adjusted OR (95% CI) | p | |
Age, yr | 0.98 (0.95–1.01) | 0.131 | 0.97 (0.93–1.001) | 0.059 |
Female | 0.71 (0.30–1.71) | 0.448 | 0.53 (0.18–1.54) | 0.241 |
Body mass index, kg/m2 | 0.93 (0.93–1.11) | 0.772 | 0.92 (0.82–1.04) | 0.195 |
COPD or asthma | 0.37 (0.07–2.01) | 0.249 | 0.93(0.11–7.76) | 0.946 |
Chronic heart disease | 2.74 (0.76–9.91) | 0.123 | 0.62 (0.09–4.32) | 0.628 |
Indication | ||||
Others | Ref | Ref | ||
Lung cancer | 0.53 (0.15–1.95) | 0.343 | 0.69 (0.13–3.66) | 0.665 |
Infection | 0.90 (0.31–2.59) | 0.841 | 1.43 (0.40–5.05) | 0.581 |
Interstitial lung disease | 0.98 (0.22–4.28) | 0.976 | 1.72 (0.29–10.06) | 0.548 |
Procedure | ||||
Inspection only | Ref | Ref | ||
Inspection with bronchoscopic biopsy | 0.92 (0.25–3.39) | 0.896 | 0.27 (0.04–1.64) | 0.154 |
Inspection with BAL and/or TBLB | 0.92 (0.19–4.40) | 0.913 | 0.67 (0.10–4.55) | 0.684 |
Sedative drug | ||||
Midazolam/propofol | Ref | Ref | ||
Remifentanyl | 7.70 (2.74–21.65) | < 0.001 | 15.88 (4.14–60.90) | < 0.001 |